884004-48-2

Usage

Uses

2-Amino-4-chloronicotinaldehyde is a useful synthetic compound.

Upstream product

• 19798-80-2 2-Amino-4-chloropyridine 
• 130721-78-7 tert-butyl (4-chloropyridin-2-yl) carbamate 
• 68-12-2 N,N-dimethyl-formamide 
• 868736-42-9 tert-butyl N-(4-chloro-3-formylpyridin-2-yl)carbamate 

Downstream Products

• 1466514-96-4 C₂₀H₁₇ClN₄O₅ 
• 1466514-32-8 C₂₄H₂₃ClFN₅O₄ 
• 1466514-55-5 C₂₅H₂₃FN₆O₄ 
• 1466514-37-3 C₂₈H₂₇ClFN₇O₄ 
• 1466514-72-6 2-amino-5-bromo-4-chloropyridine-3-carbaldehyde 
• 1466514-74-8 C₁₆H₁₀BrCl₂N₃O₂ 
• 1466514-90-8 C₂₂H₁₉BrCl₂N₄O₃ 
• 1466514-91-9 C₂₆H₂₇BrClN₅O₃ 
• 1466514-29-3 C₂₆H₂₆ClN₅O₃ 
• 1466514-94-2 C₂₂H₂₀BrCl₂N₃O₄ 
• 1466514-95-3 C₂₉H₃₃ClN₄O₇ 
• 832692-66-7 7-[3-(trifluoromethyl)pyridin-2-yl]-N-[5-(trifluoromethyl)-pyridin-2-yl]-1,8-naphthyridin-4-amine 

Relevant academic research and scientific papers

Fused ring compounds as FGFR4 inhibitors

The heart toxicity is low. High selectivity as FGFR4 inhibitor fused ring compounds, pharmaceutical compositions containing said compounds, useful intermediates and for preparing said compounds, and methods of treating cell proliferative diseases such as cancer using the compounds of the present invention.

INHIBITORS OF BRUTON'S TYROSINE KINASE

The present invention relates to a new compound of formula I: or pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein: V1 is C or N, V2 is C(R2) or N, whereby if V1 is C then V2 is N, if V1 is C then V2 is C(R2), or if V1 is N then V2 is C(R2); each n, k is independently 0, 1; each R2, R11 is independently H, D, Hal, CN, NR'R", C(O)NR'R", C1-C6 alkoxy; R3 is H, D, hydroxy, C(O)C1-C6 alkyl, C(O)C2-C6 alkenyl, C(O)C2-C6 alkynyl, C1-C6 alkyl; R4 is H, Hal, CN, CONR'R", hydroxy, C1-C6 alkyl, C1-C6 alkoxy; L is CH2, NH, O or chemical bond; R1 is selected from the group of the fragments, comprising: Fragment 1, Fragment 2, Fragment 3 each A1, A2, A3, A4 is independently CH, N, CHal; each A5, A6, A7, A8, A9 is independently C, CH or N; R5 is H, CN, Hal, CONR'R", C1-C6 alkyl, non-substituted or substituted by one or more halogens; each R' and R" is independently selected from the group, comprising H, C1-C6 alkyl, C1-C6 cycloalkyl, aryl; R6 is selected from the group: [formula II] each R7, R8, R9, R10 is independently vinyl, methylacetylenyl; Hal is CI, Br, I, F, which have properties of inhibitor of Bruton's tyrosine kinase (Btk), to pharmaceutical compositions containing such compounds, and their use as pharmaceuticals for treatment of diseases and disorder.

CYTOMEGALOVIRUS INHIBITOR COMPOUNDS

Compounds of Formula (I) wherein n, A, R1, R2, R3 and R5 are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.

NAPHTHYRIDINONE DERIVATIVES AS INHIBITORS OF CYTOMEGALOVIRUS DNA POLYMERASE

Compounds of Formula (I) wherein n, m, R1, R2, R3, R4, R5 and R6 are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.

Discovery of novel 6,6-heterocycles as transient receptor potential vanilloid (TRPV1) antagonists

The transient receptor potential cation channel, subfamily V, member 1 (TRPV1) is a nonselective cation channel that can be activated by a wide range of noxious stimuli, including capsaicin, acid, and heat. Blockade of TRPV1 activation by selective antago

HETEROARYL SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES

Heteroaryl substituted quinolin-4-ylamine analogues of Formula I are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

SUBSTITUTED PYRIDAZINYL-AND PYRIMIDINYL-QUINOLIN-4-YLAMINE ANALOGUES

Substituted pyridazinyl- and pyrimidinyl-quinolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associat

SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES

Substituted quinolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor